Detection of hepatitis b surface gene mutation in carrier children with or without immunoprophylaxis at birth

Journal of Infectious Diseases

Volumn 176, Issue 2, 1997, Pages 427-430

  Lee, Ping Ing ^a   Chang, Luan Yin ^a,b   Lee, Chin Yun ^a   Huang, Li Min ^a   Chang, Mei Hwei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY;

AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; BIRTH; CHILD; DNA SEQUENCE; GENE MUTATION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; VACCINATION; VIRUS CARRIER; VIRUS DETECTION; VIRUS NEUTRALIZATION;

EID: 0030744532     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514060     Document Type: Article

References (31)

1. Beasley RP, Hwang LY, Lin CC, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135-41.
2. Lee CY, Huang LM, Chang MH, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn of hepatitis B e antigen-positive carrier mothers. Pediatr Infect Dis J 1991;10:299-303.
3. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to hepatitis B e antigen-positive mothers. J Pediatr 1995;126:716-21.
4. Lee PI, Lee CY, Huang LM, Chen JM, Chang MH. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. Vaccine 1995;13:1685-9.
5. Lee SD, Lo KJ, Wu JC, et al. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986;6:369-73.
6. Lin HH, Lee TY, Chen DS, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987;111:877-81.
7. Mitsuda T, Yokota S, Mori T, et al. Demonstration of mother-to-infant transmission of hepatitis B virus by means of polymerase chain reaction. Lancet 1989;2:886-8.
8. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-9.
9. Waters JA, Kennedy M, Voet P, et al. Loss of the common "a" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992;90:2543-7.
10. Harrison TJ, Hopes EA, Oon CJ, Zanetti AR, Zuckerman AJ. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol 1991;13(suppl 4):105-7.
11. Fujii H, Moriyama K, Sakamoto N, et al. Gzy145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 1992;184:1152-7.
12. Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992;32:264-8.
13. Karthigesu VD, Allison LMC, Fortuin M, Mendy M, Whittle HC, Howard CR. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994;75:443-8.
14. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995;13:699-702.
15. Hino K, Okuda M, Hashimoto O, et al. Glycine-to-arginine substitution at codon 145 of HBsAg in two infants born to hepatitis B e antigen-positive carrier. Dig Dis Sci 1995;40:566-70.
16. Brown SE, Howard CR, Zuckerman AJ, Steward MW. Affinity of antibody response in man to hepatitis B vaccine determined with synthetic peptides. Lancet 1984;2:184-7.
17. Howard CR, Stirk HJ, Brown SE, Steward MW. Towards the development of synthetic hepatitis B vaccines. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988:1094-101.
18. Gerety RJ, Tabor E, Purcell RH, Tyeryar F. Summary of an international workshop on hepatitis B vaccines. J Infect Dis 1979;140:642-8.
19. Ashton-Rickardt PG, Murray K. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol 1989;29:196-203.
20. Bruce SA, Murray K. Mutations of some critical amino acid residues in the hepatitis B virus surface antigen. J Med Virol 1995;46:157-61.
21. Lee CY, Lee PI, Huang LM, Chen JM, Chang MH. A simplified schedule to integrate the hepatitis B vaccine into an expanded program of immunization in endemic countries. J Pediatr 1997;130:981-6.
22. Haliassos A, Chomel JC, Tesson L, et al. Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res 1989;17:3606.
23. Will H, Reiser W, Weimer T, et al. Replication strategy of human hepatitis B virus. J Virol 1987;61:904-11.
24. Akarca US, Lok ASF. Naturally occurring hepatitis B virus core gene mutations. Hepatology 1995;22:50-60.
25. Hamasaki K, Nakata K, Nagayama Y, et al. Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B. Hepatology 1994;20:8-14.
26. Hsu HY, Chang MH, Lee CY, et al. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis 1995;171:776-81.
27. von Weizsäcker F, Pult I, Geiss K, Wirth S, Blum HE. Selective transmission of variant genomes from mother to infant in neonatal fulminant hepatitis B. Hepatology 1995;21:8-13.
28. Yamamoto K, Horikita M, Tsuda F, et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994;68:2671-6.
29. Wallace LA, Echevarria JE, Echevarria JM, Carman WF. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994;170:1300-3.
30. Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci USA 1985;82:8168-72.
31. Itoh Y, Takai E, Ohnuma H, et al. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 1986;83:9174-8.